tyrosine kinase inhibitors

Open Access
Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFβ1 and TGF-β Receptor 2 in Squamous Cell Carcinoma Cells
LENA HUBER, MANUEL THOMAS KNÜTTEL, BENEDIKT KRAMER, LENA ZAUBITZER, ANNE LAMMERT, CLAUDIA SCHERL, NICOLE ROTTER and DANIEL HÄUSSLER

Anticancer Research August 2024, 44 (8) 3287-3294; DOI: https://doi.org/10.21873/anticanres.17147
You have access
Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data
SARAH SHARMAN MOSER, LIOR APTER, JOSIE SOLOMON, GABRIEL CHODICK, MIRIANA WOLLNER and NAVA SIEGELMANN-DANIELI

Anticancer Research January 2024, 44 (1) 257-265; DOI: https://doi.org/10.21873/anticanres.16809
Open Access
Liver Metastases of Unknown Primary Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors: A Case Report and Literature Review
DAVIDE BIMBATTI, NICOLÒ CAVASIN, FRANCESCA GALUPPINI, ALESSANDRO RAGO, GAETANO RAMONDO, ELEONORA LAI, MICHELE DIONESE, ELISA ERBETTA, UMBERTO BASSO and MARCO MARUZZO

Anticancer Research May 2023, 43 (5) 2359-2365; DOI: https://doi.org/10.21873/anticanres.16401
You have access
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours
LENA FAUSKE, PERNILLE H. WÆRSTAD, IVAR HOMPLAND and ØYVIND S. BRULAND

Anticancer Research February 2022, 42 (2) 955-963; DOI: https://doi.org/10.21873/anticanres.15555
You have access
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis
SHO MITSUYA, KENJIRO TSURUOKA, KIYOE KANAOKA, TOMOYA FUNAMOTO, HIROYUKI TSUJI, NINSO MATSUNAGA, TAKAHIKO NAKAMURA, YOSUKE TAMURA, MASAFUMI IMANISHI, SOICHIRO IKEDA, YASUHITO FUJISAKA, ISAO GOTO and AKIHISA IMAGAWA

Anticancer Research October 2021, 41 (10) 5137-5145; DOI: https://doi.org/10.21873/anticanres.15331
You have access
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World
VITTORIO GEBBIA, ANDREA GIRLANDO, ALFIO DI GRAZIA, IVAN FAZIO, NICOLÒ BORSELLINO, DARIO PIAZZA, VINCENZO SERRETTA, STEFANO PERGOLIZZI, ANTONIO PONTORIERO, ALBERTO FIRENZE and MARIA ROSARIA VALERIO

Anticancer Research December 2020, 40 (12) 7037-7043; DOI: https://doi.org/10.21873/anticanres.14730
You have access
FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus
LENA HUBER, RICHARD BIRK, MANUEL KNUETTEL, NICOLE ROTTER, CHRISTOPH ADERHOLD, CLAUDIA SCHERL, ANNE LAMMERT, FREDERIC JUNGBAUER and BENEDIKT KRAMER

Anticancer Research October 2020, 40 (10) 5621-5630; DOI: https://doi.org/10.21873/anticanres.14575
You have access
Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib
KENTA YAMAMOTO, TEIJI KUZUYA, TAKASHI HONDA, TAKANORI ITO, YOJI ISHIZU, MASANAO NAKAMURA, RYOJI MIYAHARA, HIROKI KAWASHIMA, MASATOSHI ISHIGAMI and MITSUHIRO FUJISHIRO

Anticancer Research February 2020, 40 (2) 665-676; DOI: https://doi.org/10.21873/anticanres.13996
You have access
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp
JI YEONG KIM, HYUNG SIK KIM and SUNGPIL YOON

Anticancer Research July 2019, 39 (7) 3785-3793; DOI: https://doi.org/10.21873/anticanres.13527
You have access
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
ANA LAURA ORTEGA-GRANADOS, ÁNGEL ARTAL-CORTES, DAVID AGUIAR-BUJANDA, JUANA ORAMAS, JOSÉ LUIS FÍRVIDA, JAVIER DE CASTRO, JUANA CAMPILLO FUENTES, ROCÍO GORDO, RAQUEL GALÁN, JOSÉ TRIGO and on behalf of the ASPET Study Investigators

Anticancer Research March 2019, 39 (3) 1317-1328; DOI: https://doi.org/10.21873/anticanres.13244

Main menu

User menu

Search

tyrosine kinase inhibitors

Pages